POPULARITY
Categories
218 episodes with md phd
86 episodes with md phd
156 episodes with md phd
160 episodes with md phd
140 episodes with md phd
206 episodes with md phd
142 episodes with md phd
64 episodes with md phd
75 episodes with md phd
65 episodes with md phd
78 episodes with md phd
40 episodes with md phd
64 episodes with md phd
46 episodes with md phd
36 episodes with md phd
47 episodes with md phd
43 episodes with md phd
46 episodes with md phd
46 episodes with md phd
25 episodes with md phd
67 episodes with md phd
35 episodes with md phd
38 episodes with md phd
50 episodes with md phd
16 episodes with md phd
36 episodes with md phd
23 episodes with md phd
24 episodes with md phd
41 episodes with md phd
43 episodes with md phd
21 episodes with md phd
34 episodes with md phd
10 episodes with md phd
38 episodes with md phd
9 episodes with md phd
26 episodes with md phd
20 episodes with md phd
21 episodes with md phd
15 episodes with md phd
16 episodes with md phd
13 episodes with md phd
25 episodes with md phd
6 episodes with md phd
15 episodes with md phd
20 episodes with md phd
22 episodes with md phd
11 episodes with md phd
10 episodes with md phd
12 episodes with md phd
8 episodes with md phd
8 episodes with md phd
7 episodes with md phd
9 episodes with md phd
6 episodes with md phd
8 episodes with md phd
15 episodes with md phd
5 episodes with md phd
4 episodes with md phd
14 episodes with md phd
5 episodes with md phd
10 episodes with md phd
13 episodes with md phd
8 episodes with md phd
6 episodes with md phd
20 episodes with md phd
6 episodes with md phd
5 episodes with md phd
5 episodes with md phd
8 episodes with md phd
6 episodes with md phd
5 episodes with md phd
6 episodes with md phd
4 episodes with md phd
8 episodes with md phd
5 episodes with md phd
6 episodes with md phd
7 episodes with md phd
5 episodes with md phd
4 episodes with md phd
11 episodes with md phd
5 episodes with md phd
10 episodes with md phd
19 episodes with md phd
6 episodes with md phd
5 episodes with md phd
4 episodes with md phd
6 episodes with md phd
9 episodes with md phd
6 episodes with md phd
5 episodes with md phd
4 episodes with md phd
15 episodes with md phd
5 episodes with md phd
5 episodes with md phd
5 episodes with md phd
5 episodes with md phd
12 episodes with md phd
4 episodes with md phd
5 episodes with md phd
4 episodes with md phd
4 episodes with md phd
16 episodes with md phd
6 episodes with md phd
3 episodes with md phd
5 episodes with md phd
4 episodes with md phd
3 episodes with md phd
6 episodes with md phd
4 episodes with md phd
12 episodes with md phd
3 episodes with md phd
4 episodes with md phd
5 episodes with md phd
4 episodes with md phd
4 episodes with md phd
2 episodes with md phd
2 episodes with md phd
2 episodes with md phd
4 episodes with md phd
4 episodes with md phd
10 episodes with md phd
2 episodes with md phd
4 episodes with md phd
3 episodes with md phd
3 episodes with md phd
9 episodes with md phd
4 episodes with md phd
68 episodes with md phd
3 episodes with md phd
3 episodes with md phd
3 episodes with md phd
4 episodes with md phd
4 episodes with md phd
2 episodes with md phd
2 episodes with md phd
In this episode, Boris Pasche, MD, PhD, FACP, President and Chief Executive Officer of Barbara Ann Karmanos Cancer Institute and Oncology Department Chair at Wayne State University, joins the podcast to discuss navigating uncertainty in today's healthcare environment. He shares insights on evolving therapy services and highlights emerging breakthroughs in oncology that are shaping the future of cancer care.
Three simple habits from a top doctor who says you should never take swallowing or your voice for granted.You don't think about swallowing or your voice until something goes wrong — and then it's everything. In this episode, Dr. Juna talks with Dr. Peter Belafsky MD, PhD — laryngologist, Director of the Center for Voice and Swallowing at UC Davis, and co-founder of Reflux Gourmet — about the small daily habits that prevent big problems. Dr. Belafsky breaks down his three biggest levers against acid reflux, why most people don't actually need daily acid blockers, surprising facts, and a hack that could preserve your voice for life.It's a RELAX TO SOAR™ conversation about eating clean and the tiny, repeatable habits that protect the body you take for granted.The habits that prevent reflux are small, daily, and easy to forget — exactly why the RELAX TO SOAR™ system was made to keep it all on autopilot.Control your time and cognitively offload your health with the 6-month RELAX TO SOAR™ system.Sign up now to get free email support with your planner:mindbodyspace.com/storeLinks:Reflux Gourmet → https://refluxgourmet.comHashtags: #AcidReflux #GERD #SilentReflux #LPR #RefluxGourmet #VoiceHealth #Swallowing #Laryngology #GutHealth #LifestyleMedicine #RelaxToSoar #MindBodySpace
In today's episode, we spoke with Adam M. Brufsky, MD, PhD, about the FDA approval of gedatolisib (Revtorpyk) plus fulvestrant (Faslodex), with or without palbociclib (Ibrance), for the treatment of adult patients with hormone receptor–positive, HER2-negative advanced breast cancer without a PIK3CA mutation following progression on or after treatment with 1 or more lines of endocrine therapy in the metastatic setting. Dr Brufsky is a professor of medicine and the associate division chief for the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh School of Medicine; as well as medical director of the Magee-Women's Cancer Program, associate director for clinical investigations, and codirector of the Comprehensive Breast Cancer Center at the University of Pittsburgh Medical Center Hillman Cancer Center, in Pennsylvania.In our exclusive interview, Dr Brufsky highlighted the significance of this approval, key efficacy and safety data from Study 1 of the phase 3 VIKTORIA-1 trial (NCT05501886) that supported this regulatory decision, and what the future may hold for metastatic breast cancer management strategies.
In this episode of PeDRA Pearls, Jenn Dawson welcomes Delaney Ding, PeDRA's Research Fellow, to discuss his journey as an MD-PhD student and his work at the intersection of pediatric dermatology, epidemiology, data science, and patient advocacy. Delaney shares insights from his research on skin cancer among people living with HIV, as well as his commitment to patient-centered research, vulnerable populations, and meaningful outcomes. He also discusses the importance of mentorship and collaboration, as well as the unexpected opportunities that can shape a research career. As PeDRA's inaugural Research Fellow, Delaney shares his vision for advancing research to improve patient outcomes and strengthen the pediatric dermatology community.This episode is presented by Disc Medicine. Although Disc Medicine provided funding for this PeDRA Pearls Podcast, the contents of the podcast were developed independently by PeDRA. Learn more about Disc Medicine.
Donate to the Institute: https://givenow.nova.edu/assaf-family-and-community-me-cfs-endowed-fund-campaign/?a=1 In today's episode, Makena Thompson sits down with Dr. Jonas Axelsson, a Swedish physician-scientist specializing in post-viral diseases, to address one of the most urgent questions in ME/CFS and long COVID care: why do standard blood tests keep coming back normal when patients clearly are not well? Dr. Axelsson breaks down what standard diagnostic panels actually measure, why cellular oxidative stress and mitochondrial dysfunction remain invisible to serum chemistry, and why a clean blood test is not the same as a healthy patient. He also outlines two distinct immune patterns he has identified in this patient population, explains why current criteria-based diagnosis is not sensitive enough to distinguish between them, and shares why he believes validated diagnostic tools and mechanism-based treatments are within reach within five years. Learn why your labs can be normal and your illness can still be very real. Tune in to Hope and Help For Fatigue and Chronic Illness. Dr. Jonas Axelsson is a physician specializing in Internal Medicine, Nephrology, Clinical Immunology, and Transfusion Medicine. From 2019 to 2024, he served as Medical Director of the Center for Aphresis and Stem Cell Therapy at Karolinska University Hospital in Stockholm, Sweden. From 2016 to 2022, he was an Associate Professor at Karolinska Institutet in Stockholm, Sweden. LinkedIn: https://www.linkedin.com/in/jonas-axelsson-484853327 Makena Thompson is a Research Program Manager at the Institute for Neuro-Immune Medicine at Nova Southeastern University. Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet. Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com Instagram: https://www.instagram.com/hayliepomroy Facebook: https://www.facebook.com/hayliepomroy YouTube: https://www.youtube.com/@hayliepomroy/videos LinkedIn: https://www.linkedin.com/in/hayliepomroy/ X: https://x.com/hayliepomroy Thank you for tuning in to the Hope and Help For Fatigue and Chronic Illness Podcast. Sign up today for our newsletter.
In today's episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine in Florida.In our exclusive interview, Dr Trent discussed currently approved TKIs for patients with gastrointestinal stromal tumor (GIST), including imatinib (Gleevec), sunitinib (Sutent), regorafenib (Stivarga), and ripretinib (Qinlock). Trent dove into how these TKIs have improved outcomes for patients and touched on common adverse effects seen with these therapies, as well as how to manage these toxicities and maintain treatment adherence among patients. He also looked to liquid formulations of TKIs that are in development and the benefits they would bring to GIST management.
Brain aging does not start when memory loss shows up. It starts around age 25, decades before anyone notices anything is different. By the time a symptom appears, the window for the highest-leverage prevention has usually already closed.Today I'm talking with Dr. Christin Glorioso, an MD and PhD who has spent her career studying Alzheimer's, partly because of her own family history and partly because she carries the ApoE4 gene herself. She has since used her own brain scans, blood work, and lifestyle changes to lower her own brain age, and she's built a company around helping other people do the same.This conversation covers what actually causes Alzheimer's versus what we got wrong for decades, why the brain can grow back the same way muscle does, and why a ten minute daily habit has better evidence behind it than any drug currently on the market. We also get into hormone therapy, cholesterol, the ketogenic diet, and why women are so consistently underserved on all three.Join the most comprehensive *female-specific community for health and longevity optimization.* After over a decade dedicated to human performance and women's health, I created this space to share everything you need to know to optimize health and lifespan. Inside, you'll get access to exclusive protocols, live Q&As, the latest female longevity science, and a private, supportive community of like-minded women.https://kayla-barnes-lentz.circle.so/checkout/become-a-memberConnect with Kayla:Instagram: https://www.instagram.com/kaylabarnes/TikTok: https://www.tiktok.com/@femalelongevityTwitter:https://x.com/femalelongevityWebsite:https://www.kaylabarnes.com/Spotify: https://open.spotify.com/show/4OLWWn22RGB0argbRPvAaQ?si=8e91b3c9e0ce4054Apple: https://podcasts.apple.com/us/podcast/longevity-optimization-with-kayla-barnes-lentz/id1591130227Follow Her Female Protocol: https://www.protocol.kaylabarnes.comLearn more about Dr Christin Glorioso, MD, PhDLinkedIn: https://www.linkedin.com/in/christin-glorioso-md-phd-39627719/ Website: https://www.neuroagetx.com/#BrainHealth #AlzheimersPrevention #DementiaPrevention #BrainAging #Neuroscience #CognitiveHealth #HRT #Perimenopause #Menopause #Cholesterol #Nootropics
This week, J.John speaks with Francis Collins, who served as the director of the National Institute of Health for 12 years and directed the National Human Genome Research Institute. During this conversation, Francis reflects on his journey from atheism to faith, sparked by a simple yet profound question: "What do you believe?"
What if the mental health crisis isn't simply a crisis of the mind—but a crisis of the environment we've created for the brain? In this fascinating conversation with Dr. Dave Rabin, one of my best podcasts ever, we explore why our nervous systems are being pushed beyond what they evolved to handle, how chronic overstimulation is fueling everything from burnout to dementia, why HRV is one of the most important biomarkers of longevity and the remarkable science and results of the ApolloNeuro.Dr. David M. L. Rabin, MD, PhD, is a translational neuroscientist, psychiatrist, entrepreneur & inventor on a mission to cure mental illness. He has been studying the impact of chronic stress in humans for over 20 years, focusing on trauma, addiction, and human performance. Dr. Rabin is a Senior Research Scientist at the Institute for Human and Machine Cognition, the Chief Medical Officer and co-founder at Apollo Neuroscience, the Executive Director of The Board of Medicine nonprofit medical board, and the Medical Director of The Apollo Clinic. Dr. Rabin is also the author of A Simple Guide to Being Alive (2026). At the Apollo Clinic, Dr. Rabin and his team collaborate with clients and patients, empowering them to take control of their mental and physical health by tapping into the natural ability for the body to adapt and heal itself. ContactWebsite - https://www.drdave.io Website - https://apolloneuro.com Join us as we explore:Why the mental health crisis is at the core a cognitive and neurological habitat mismatch emergency - things are too much, too fast and too loud and we are overstimulated, overwhelmed and overreactive.How an overstimulated world has crashed the glympathic system and led to the fact dementia is now the number one killer in multiple countries.The three major categories of chronic, acute nervous system overstimulation.Measuring overstimulation subjectively and critically objectively with data and using technology to curate the habitat required for a healthy nervous system.Why HRV is the true longevity signal, and how ApolloNeuro can elevate your HRV sustainably.How Dr Rabin used ApolloNeuro to move his HRV from the 20s to averaging over 100 ms and hitting heights of 220 ms.Dr Rabin's 17 clinical trials prove scientifically the ApolloNeuro works to improve REM, deep sleep, decrease burnout and elevate HRV.Dr Rabin's new book “A Simple Guide to Being Alive”, and his three most important guidelines.MentionsScience - ApolloNuero Backed by Science, https://apolloneuro.com/pages/apollo-neuro-researchSupport the showFollow Steve's socials: Instagram | LinkedIn | YouTube | Facebook | Twitter | TikTokSupport the show on Patreon:As much as we love doing it, there are costs involved and any contribution will allow us to keep going and keep finding the best guests in the world to share their health expertise with you. I'd be grateful and feel so blessed by your support: https://www.patreon.com/MadeToThriveShowSend me a WhatsApp to +27 64 871 0308. Disclaimer: Please see the link for our disclaimer policy for all of our content: https://madetothrive.co.za/terms-and-conditions-and-privacy-policy/
Sarah Urbut is a physician-scientist at Harvard Medical School and the Massachusetts General Research Institute. She and her colleagues published a landmark paper in Nature on patient health journeys for 3 different cohorts—the Mass General Brigham patients, the UK Biobank, and the All of Us research program—with a cumulative 683,000 individuals, 348 diseases, and up to 52 years of follow-up. Integrating electronic medical records and polygenic risk scores (N=36). An AI model was developed and validated called ALADYNOULLI, with each individual represented latent disease signatures (N=21), mathematically and biologically driven. An example of a patient's dynamic life journey (health arc) is provided in the Figure below (adapted from the paper, made with NotebookLM). The longitudinal story for each individual is key here. Using a Gaussian process, the risk continually shifts like a GPS navigation when you make a wrong turn and you are re-routed. Considerable effort was dedicated to addressing selection bias with inverse probability weighting.Here are 20 temporal pattern signatures for the UK Biobank cohort, which help to provide the biologic mechanism of a person's disease, as shown for multiple conditions like heart attack, breast cancer, and depression. That is, the same disease phenotype can link to different genomic pathway underpinnings. An example for breast cancer could be related to signature 8 or signature 7; the latter tied to inflammation and metabolic abnormalities. This biological pattern could also be used to detect likely medication failure (such as SSRI treatment for depression) and predict rare diseases.In fact, the model was used to discover genomic signatures for different diseases, as shown below.This model predicted 1 and 10-year risk of diseases at the individual level and far surpassed routinely used clinical prediction calculators such as the pooled cohort equation (PCE) for coronary artery disease (0.89 vs 0.68, respectively, 1-year risk ) and the GAIL model for breast cancer (0.783 vs 0.54, respectively). ALADYNOULLI also surpassed accuracy for precision when compared with the recent Delphi-2M model that I wrote about hereThe ALADYNOULLI paper is packed with information and equations and is not easy to get through without a sophisticated math background. That's why the summary infographic below (made by Notebook LM) may be helpful to grasp its main findings Prediction of Your Health Trajectory in Context The new model substantively adds to many other recent reports that include Delphi 2M, APOLLO, and AURORA that predict future health events up to 20 years out. Each of these models were different with respect to inputs, how patient data were represented (tokens, embeddings, or latent states), and prediction outputs as briefly summarized in the Table I made below. Notably, the inputs are complementary and likely additive, such that the deeper and longer (longitudinally) the data re for each individual, the better predictive accuracy will be possible. Adding to these models are many specific disease prediction (e.g. cancer, asthma, diabetes, neurodegenerative diseases) and sources of data (such as sleep lab, wearables, or high-throughput proteomics).We are now seeing intense efforts at medical forecasting which will continue to evolve and something that was not previously possible in patient care. What I mean is that we could provide a rough sense of a patient's risk for, let's say Alzhiemer's disease, but could not temporally place when it might occur. Age 65 or 95? It makes a huge difference. And so does the ability to apply counterfactuals, what-if scenarios for the individuals to reduce the risk, markedly defer a condition's appearance, or even fully prevent it. That's why ALADYNOULLI adds yet another dimension, different methodology, multiple patient cohorts, and novel findings that further add to a new prediction and prevention dimension of medical practice. It couldn't have been done with multimodal AI.Note to readers: I wrote this post entirely. There was no AI used except to generate 3 Figures by Notebook LM (Figure 1,3 and 4) as noted. Figure 2 above is from the Supplemental information of the paper. I have no COI related to this post.******************************A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you're not a subscriber, please join!If you found this interesting PLEASE share it!Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 61 summer interns here with us now! These are high school, college and medical students selected from thousands of applicants. We couldn't do this expanded program without the funds coming in through Ground Truths.And thank you Harshi Peiris, Ph.D., DOCTOR KLOVER
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting HER2, MET and KRAS G12C — John V Heymach, MD, PhD CME information and select publications
Dr. Lowan Stewart is not just someone who opened a ketamine clinic. He is someone who built the infrastructure for an entire country to access it.In this conversation, Sam sits down with Dr. Stewart, an emergency physician who co-founded the first ketamine clinic in New Mexico in 2016, brought ketamine therapy to Norway two years later, established the first public ketamine treatment unit in Scandinavia, and played a central role in Norway becoming the first country in the world to approve national public reimbursement for off-label ketamine in treatment-resistant depression.What makes Dr. Stewart's story particularly resonant for our audience is how familiar the starting point will feel. An EM physician who loved his work but felt the limits of what emergency medicine could do for the river of suffering flowing through the department. A side project that became a calling. An uphill battle against institutional skepticism that most providers in this space will recognize immediately.He also brings a perspective on the future of psychedelic medicine that is worth hearing. His argument is straightforward: ketamine is not just a treatment. It is the infrastructure that will make everything else, psilocybin, MDMA, and what comes after, possible in clinical and public health settings. Getting ketamine right now is how the field prepares for what is coming next.This is a wide-ranging conversation covering career pivots, pioneering in resistant systems, the mechanics of moving a national healthcare system, and the daily reality of doing work that genuinely transforms lives.What you'll gain:• The full arc of Dr. Stewart's career pivot from emergency medicine to ketamine therapy, including what pushed him toward something with more systemic and sustainable impact than the ER could offer• A firsthand account of what it actually looks like to be the first mover in a resistant healthcare system, from opening the first ketamine clinic in New Mexico to fighting a formal complaint from the Norwegian Psychiatric Association• How Dr. Stewart built the first public ketamine treatment unit in Scandinavia and the strategy behind getting ten major Norwegian hospitals to implement ketamine therapy simultaneously through a multi-site clinical trial• What Norway's landmark decision to become the first country in the world to approve national public reimbursement for off-label ketamine in treatment-resistant depression means for the global field and what other countries can learn from it• Why Dr. Stewart believes ketamine is not just a treatment but the infrastructure that will determine how ready clinical and public health systems are when psilocybin, MDMA, and other psychedelic medicines arrive• His honest reflection on why this work is worth it, including what it feels like to shift from focusing on the quantity of life in the ER to focusing on the quality of life in ketamine therapyEpisode 62 show notes:00:00:00 Teaser: "Once somebody says, 'I'm alive today because of this treatment,' you can't not do it."00:00:24 Episode Introduction00:02:19 Sam Welcomes Dr. Lowan Stewart00:02:53 Background Overview: Emergency Medicine, Norway, and the Journey to Ketamine00:08:56 Why Neuroscience: Starting an MD-PhD and the Rat Brains Advice00:10:09 From Space Medicine Dreams to Emergency Medicine Reality00:12:14 The Decision Point: Going Away from EM or Toward Something New?00:15:37 Opening the First Ketamine Clinic in New Mexico: What the Ketamine World Looked Like in 201600:17:55 Bringing Ketamine to Norway: Opening Axon Clinic in 201800:20:06 Approaching the Norwegian Psychiatric Association and Health Department with the Data00:26:40 Psychiatrist Skepticism: "I Don't Know What to Do with These Patients If They're Fine"00:28:29 The Formal Complaint from the Norwegian Psychiatric Association00:31:23 Establishing the First Public Ketamine Treatment Unit in Scandinavia00:34:34 Axon Clinic's Acquisition by Awaken Life Sciences and the Ukraine War Impact00:40:18 Norway's Landmark Approval: National Public Reimbursement for Off-Label Ketamine00:44:20 The Multi-Site RCT Strategy: Implementing Ketamine Across Ten Major Norwegian Hospitals00:50:17 Why Ketamine Gets Overlooked at Psychedelic Conferences and Why That Needs to Change00:55:14 One Piece of Advice for Any EM Physician or Clinician Considering This Pivot00:58:34 Rapid-Fire Questions00:59:07 How Dr. Stewart De-Stresses: Cold Ocean Swims and Sauna in Norway01:02:17 How to Connect with Dr. Lowan Stewart01:04:03 Episode EndingThanks for listeningConnect with Dr. Stewart at:Clinic Website - Axonklinikken http://axon.no/ Email: lowan@axon.noLinkedin: https://www.linkedin.com/in/lowan-stewart-27349616/
In today's episode, we spoke with Solange Peters, MD, PhD. Dr Peters is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of Lausanne in Switzerland. In our exclusive interview, Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in non–small cell lung cancer (NSCLC), rather than sequencing them. She noted that prior attempts to combine or sequence bevacizumab (Avastin) with checkpoint inhibitors yielded only modest signals, hampered by bevacizumab's long half-life and class-specific toxicities including bleeding risk that historically excluded patients with squamous cell carcinoma. By contrast, PD-L1/VEGF bispecifics such as pumitamig carry a significantly shorter half-life of approximately 5 to 6 days, resulting in a similar toxicity category but with lower rates of high-grade events and a broadened eligible population.She highlighted the mechanistic rationale for this combination, explaining that VEGF and PD-L1 co-targeting appears to remodel the tumor microenvironment cooperatively, bringing cancer cells into closer proximity with T cells. In the case of PD-L1/VEGF bispecifics, a macromolecular structure forms in the tumor microenvironment that leads to internalization of PD-L1, creating a dual blockade of the PD-1/PD-L1 pathway beyond simple receptor occupancy.Dr Peters then discussed data presented at the 2026 ASCO Annual Meeting from the phase 2/3 ROSETTA Lung-02 trial (NCT06712316) evaluating pumitamig plus chemotherapy in the first-line setting. She described the activity observed across all PD-L1 expression strata, including in PD-L1–negative patients, who comprised up to 70% of the nonsquamous population and achieved response rates above 50% as particularly compelling. She also addressed the dose selection rationale, noting that the 1500-mg dose demonstrated the optimal pharmacodynamic activity and favorable risk-benefit profile for phase 3 advancement.Finally, Dr Peters offered broader perspective on the increasingly competitive PD-L1/VEGF bispecific landscape, including the parallel development of ivonescimab. She suggested that differences in clinical trial design including patient population, inclusion and exclusion criteria, and end point ambition may ultimately differentiate agents more than mechanism alone, and emphasized that global data will be essential to shaping regulatory and clinical practice decisions.
In this episode of the Psychedelic Medicine Podcast, Alexander Lebedev, MD, PhD joins to discuss psychedelic medicine and psychosis. Dr. Lebedev is a physician-scientist, medical AI engineer, and entrepreneur working at the frontier of health and technology. His work spans collective societal dynamics, psychedelics, and medical AI; he leads Lebedev Labs and is co-founder of Dreamseer and Once Wellbeing Center. In this conversation, Dr. Lebedev explores the complex relationship between psychedelics and psychosis, examining what decades of research—and more recent clinical evidence—actually tell us about the risks. He explains why individuals with personal or family histories of psychotic disorders are typically excluded from clinical trials, clarifies the distinction between transient psychotic experiences and chronic psychotic disorders, and discusses why current evidence has not established a causal link between psychedelic use and persistent psychosis in screened populations. Throughout the discussion, Dr. Lebedev emphasizes the importance of careful screening, preparation, integration, and context, arguing that psychedelics should be understood through both scientific and phenomenological lenses rather than simplistic assumptions about safety or danger. In this episode, you'll hear: What inspired Dr. Lebedev to study psychedelics and psychosis Why psychedelics became associated with psychosis and how that perception developed historically Why case reports of psychotic episodes following psychedelic use are not definitive to establish a causal link between the two How the lenses and frameworks we employ can significantly color how we understand psychosis and altered states of consciousness The role of set, setting, sleep, substance use, and integration in reducing psychological risks How psychedelic experiences overlap with—and differ from—psychotic states from a phenomenological perspective The intersection of psychosis and bipolar disorder and the relevance of this overlap to psychedelic medicine Why researchers are beginning to reconsider whether certain psychosis-spectrum populations should eventually be studied under carefully controlled conditions Quotes: "The first framework within which psychedelics were studied and considered was the psychotomimetic framework, meaning that they were considered as tools that are supposed to mimic psychotic states." [9:22] "In the pre-prohibition era, psychedelics were tested on very large populations of different patients—including people with psychosis spectrum disorders, including people with schizophrenia spectrum disorders—with some mixed results. But there was already some data indicating that from a populational perspective, from a statistical link, we didn't have clear indication, even back then, that that link [between psychedelics and psychosis] exists." [12:48] "Interestingly, unlike for cannabis, for tobacco, for some other substances, this link [with psychosis] was not verified in these large studies for psychedelics." [15:54] "If the only lens that you have is pathology, you can pathologize transformation as well. On the other hand, if the only lens that you have is spirituality, you can spiritualize the compensation that can come with the psychotic experience." [20:21] "From a phenomenological perspective, there are, of course, clear similarities [between psychedelic experiences and psychosis] . But of course, the background, the emotional content is very different. … If you read sometimes descriptions of people's mystical experiences or bad trips, sometimes they can actually on the surface look remarkably similar. What is different is the affective balance of it. And that's true for psychedelic experiences and also for psychotic experiences." [40:37] Links: Dr. Lebedev on LinkedIn Dr. Lebedev on Instagram Dr. Lebedev on Threads Once Wellbeing Center website Once Wellbeing Center on Instagram Once Wellbeing Center on LinkedIn Psychedelic Medicine Association Porangui
Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this special edition of Mind Moments, Na Tosha Gatson, MD, PhD, senior medical director of neuro-oncology and director of the Center for Neuro-Oncology at Indiana University School of Medicine, joins the podcast to discuss her career journey, philosophy of patient care, and the launch of The G.L.O.B., a new recurring NeurologyLive column dedicated to advancing health literacy in neuro-oncology. Drawing on decades of experience in neuro-oncology, clinical leadership, and mentorship, Gatson shares the motivation behind creating a platform that transforms complex oncologic concepts into practical, accessible knowledge for clinicians, patients, and caregivers alike. The conversation explores the inspiration behind The G.L.O.B., the importance of effective medical communication, lessons learned throughout Gatson's career, and the role of health literacy, shared decision-making, and health equity in modern neurologic care. She also discusses her vision for the future of the column and why improving patient understanding should remain central to both clinical practice and research. Episode Breakdown: 1:10 – Journey into neuro-oncology and career-defining experiences 4:50 – Mission and philosophy behind The G.L.O.B. 7:10 – Key themes readers can expect from the column 9:45 – Career lessons that shaped Dr. Gatson's clinical practice 16:30 – Vision for The G.L.O.B. and improving healthy literacy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
What happens when you ask ChatGPT to study every conversation you have had and tell you who you really are? One medical student did that, and what it told him changed how he sees his future in medicine. Jack Tiller is a medical student in an MD-PhD program, with doctoral work in neuroscience and neurodegeneration. This episode is based on his article "The reluctant achiever: Navigating identity in medical training," published on KevinMD. You will hear why the AI labeled him a reluctant achiever, and how a single line about having many possible lives but only one timeline stopped him cold. Jack explains how board-exam burnout, perfectionism, and an identity built on achievement all came into focus. He talks about exploring careers beyond clinical medicine, from science writing to policy, and about using AI alongside therapy to understand his own thinking. Press play to hear how AI helped one medical student see himself more clearly, and why he is giving himself permission to imagine a life beyond the path he was told to follow. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast
In today's episode, we highlighted an OncLive Peer Exchange discussion about cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) moderated by Misty D. Shields, MD, PhD. Dr Shields is an assistant professor of clinical medicine in the Department of Medicine in the Division of Hematology/Oncology at the Indiana University (IU) School of Medicine, as well as an adjunct assistant professor of medical & molecular genetics and an associate member of Experimental and Developmental Therapeutics at the IU Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis. She was joined by Triparna Sen, MD, PhD, MS, a professor at The Ohio State University in Columbus, and Ditte Primdahl, MD, an assistant professor of neurology (neuro-oncology) and neurological surgery at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.In this exclusive conversation, the experts discussed the ties between cancer-associated LEMS and small cell lung cancer. They noted that LEMS is characterized by proximal muscle weakness, hyperreflexia, and autonomic dysfunction, and that diagnostic challenges include late referral to neurology and misattribution of symptoms to cancer-related fatigue. They also highlighted key symptoms, which include proximal leg weakness, dry mouth, and blurred vision. Furthermore, they dove into treatment options for symptom control and emphasized that a multidisciplinary approach to care, including oncology, neurology, and laboratory medicine, is crucial for early LEMS diagnosis and effective management.
In today's episode, we welcomed Everett Meyer, MD, PhD, an associate professor of medicine (blood & marrow transplantation), an associate professor of pediatrics (stem cell transplantation), and an associate professor of surgery (abdominal transplantation) at Stanford Medicine in California.In the exclusive interview, Dr Meyer discussed the significance of the June 2026 FDA approval of allogeneic regulatory T cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution, and to improve chronic graft-vs-host disease (cGHVD)–free survival in the treatment of adults with hematological malignancies. Dr Meyer also broke down what the approval of Orca-T means for the transplant field, detailed the design and key outcomes from the phase 3 Precision-T trial (NCT05316701) that supported the approval, and outlined how this approach could be integrated into clinical practice.
In today's episode, we spoke with Paolo Tarantino, MD, PhD. Dr Tarantino is a breast medical oncologist and advanced fellow at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.In our exclusive interview, Dr Tarantino discussed practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting, including the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta) for first-line treatment of HER2-positive breast cancer based on findings from the phase 3 DESTINY-Breast09 trial (NCT04784715); updated safety data from the phase 3 DESTINY-Breast05 trial (NCT04622319) that indicated that T-DXd–associated interstitial lung disease is reversible with steroids, although radiation pneumonitis is non-reversible; and the phase 3 OPTIMA trial (ISRCTN42400492) results, which suggested that the PAM50 signature can identify patients who may not need chemotherapy, potentially sparing them from unnecessary treatment.
TWiP solves the case of the 39-year-old man originally from Guatemala, who moved to one of the NYC boroughs in 2023 and presented with headaches for nearly 1 year. Hosts: Vincent Racaniello, Daniel Griffin, and Christina Naula Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode Join the MicrobeTV Discord server Letters read on TWiP 284 TWiP study – information and survey New Case Recent ID consult: MD/PhD mother doing research, married with child 2 yo, female develops anal irritation, husband is fine, child is fine. Parasitic etiology is considered. Referred to academic ID providers, turns out she had this etiology considered, had received some treatment, got a little better, symptoms returned, treated again, got better, symptoms returned. Got some hard to find testing equipment, and confirm suspicion. Treat once, then again in two weeks. Not any better, still irritation. What do we do? HIV neg, no prior medical issues, no travel. Become a patron of TWiP Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DYP865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2027.Charting a New Course for Alzheimer's: Adapting Clinical Practice to Evolving Patient Needs in the Era of Early Disease Detection and Modification In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NDK865. CME/MOC/AAPA credit will be available until July 16, 2027.Innovations in Bullous Pemphigoid Management: Targeted Solutions for a Blistering Challenge In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DYP865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2027.Charting a New Course for Alzheimer's: Adapting Clinical Practice to Evolving Patient Needs in the Era of Early Disease Detection and Modification In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DYP865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2027.Charting a New Course for Alzheimer's: Adapting Clinical Practice to Evolving Patient Needs in the Era of Early Disease Detection and Modification In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DYP865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2027.Charting a New Course for Alzheimer's: Adapting Clinical Practice to Evolving Patient Needs in the Era of Early Disease Detection and Modification In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DYP865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2027.Charting a New Course for Alzheimer's: Adapting Clinical Practice to Evolving Patient Needs in the Era of Early Disease Detection and Modification In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DYP865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2027.Charting a New Course for Alzheimer's: Adapting Clinical Practice to Evolving Patient Needs in the Era of Early Disease Detection and Modification In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NDK865. CME/MOC/AAPA credit will be available until July 16, 2027.Innovations in Bullous Pemphigoid Management: Targeted Solutions for a Blistering Challenge In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.
M2 Jack Klitgaard and M4 Fallon Jung are both expecting newborns in the coming months. M2 Regan Demaris has a couple toddlers already, and CCOM Registrar and Curriculum Director Carrie Bernat had her children while putting her husband through medical school two decades ago. In short, it's the perfect group to talk about the challenges and triumphs of cuddling kids while cramming the Krebs cycle. Fallon's challenge will be how to apply for residency positions with a new little one. Jack faces starting his clinical rotations while stepping into the role of father. Fortunately, both of their spouses are going to stay at home to be the primary caregiver. Regan's toddlers came into the world before medical school and as her husband was in the Navy, which presented its own moments of terror--like how to cope with a daycare disaster while he was incommunicado on a boat somewhere. And Carrie--well, 20 years ago she was working at another medical school and having babies while her husband navigated an MD/PhD program. They were handling it well until her second child was born with a chromosomal microdeletion, upending carefully laid plans.
Today, Alan M. Garber, President, Harvard University sat down with Economic Club Chairman David M. Rubenstein.They discussed how the nation's leading academic institutions are navigating a period of rapid technological and financial change.
Send us Fan MailWhat are the most common eye injuries in children—and how can parents help prevent them?In this episode of Your Child Is Normal, Dr. Jessica Hochman sits down with Dr. Aaron Nagiel, pediatric retinal specialist and Chief of the Retina Division at Children's Hospital Los Angeles, to discuss children's eye health, vision safety, and the latest breakthroughs in retinal care.Dr. Nagiel explains how the retina works, common retinal conditions seen in children, and the warning signs parents should never ignore. He shares real-world stories about sports injuries, Nerf gun accidents, and laser pointer injuries that can lead to permanent vision loss, while offering practical advice on prevention and eye protection.They also discuss:• Common eye injuries in children and how to prevent them• When a red eye is concerning—and when it isn't• Warning signs of retinal disease• The role of screens, outdoor play, and dry eyes• Why children should wear prescribed glasses consistently• When eye symptoms warrant an urgent evaluation• Exciting advances in gene therapy and the future of pediatric retinal careThis episode is packed with practical takeaways that can help parents recognize problems early, protect their children's vision, and know when to seek specialized care.Dr. Aaron Nagiel is a pediatric retinal specialist at Children's Hospital Los Angeles and USC Roski Eye Institute, where he cares for children with retinal diseases, eye trauma, retinopathy of prematurity, and inherited retinal disorders. In collaboration with the Center for Personalized Medicine, he leads a state-of-the-art program specializing in the diagnosis and treatment of genetic eye disease, including gene therapy surgery.Dr. Aaron Nagiel earned his bachelor's degree from Harvard University summa cum laude, and then underwent combined MD and PhD training at Cornell University and The Rockefeller University in New York City. His PhD work was supported by an NIH fellowship and contributed to our understanding of how synapses form in the developing brain. After an internship at Memorial Sloan-Kettering Cancer Center, Dr. Nagiel completed both ophthalmology residency and vitreoretinal fellowship at the renowned Stein Eye Institute at UCLA.To contact Dr Nagiel:Please call 323-361-2347 or check out his websiteYour Child is Normal is the trusted podcast for parents, pediatricians, and child health experts who want smart, nuanced conversations about raising healthy, resilient kids. Hosted by Dr. Jessica Hochman — a board-certified practicing pediatrician — the show combines evidence-based medicine, expert interviews, and real-world parenting advice to help listeners navigate everything from sleep struggles to mental health, nutrition, screen time, and more. Follow Dr Jessica Hochman:Instagram: @AskDrJessica and Tiktok @askdrjessicaYouTube: Ask Dr JessicaShop my favorite products for kids on Amazon hereIf you are interested in placing an ad on Your Child Is Normal click here or fill out our interest form.For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA The information ...
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of treating multiple myeloma, focusing on two challenging cases from the community. Joined by experts Marco Davila, MD PhD, from Roswell Park Comprehensive Cancer Center and Krina Patel, MD MSc, from MD Anderson Cancer Center, they discuss the nuances of treatment options for patients experiencing disease relapse post-transplant and disease progression while on maintenance therapy. Key topics included: The importance of thorough workup and repeat cytogenetics in high-risk multiple myeloma patients The debate between CAR T-cell therapy and bispecific antibodies as treatment options Strategies for managing patients with comorbidities and the role of shared decision-making in treatment planning Insights into the side effects associated with CAR-T and bispecific therapies, including infection risks and neurological symptoms Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explored the latest advancements in multiple myeloma treatment and the exciting potential for achieving long-term remission and even cure in select patient populations. Don't forget to like, subscribe, and hit the notification bell for more insightful discussions on oncology! #MultipleMyeloma, #CARTtherapy, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NUP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until July 12, 2027.All-in for Transthyretin Amyloidosis: Refining Team-Based Approaches to Diagnosis, Treatment, and Lifesaving Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NUP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until July 12, 2027.All-in for Transthyretin Amyloidosis: Refining Team-Based Approaches to Diagnosis, Treatment, and Lifesaving Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NUP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until July 12, 2027.All-in for Transthyretin Amyloidosis: Refining Team-Based Approaches to Diagnosis, Treatment, and Lifesaving Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NUP865. CME/NCPD/CPE/AAPA/IPCE credit will be available until July 12, 2027.All-in for Transthyretin Amyloidosis: Refining Team-Based Approaches to Diagnosis, Treatment, and Lifesaving Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
OpenEvidence didn't leave Europe because of regulation alone — its ad-and-data business model never fit the European market. When OpenEvidence, the $12B clinical AI search platform used daily by over 40% of US physicians, withdrew from the EU and UK in April 2026 citing the EU AI Act, European clinicians lost a tool many had quietly adopted. In this episode, Philippe Habets — physician-scientist and CEO of Amsterdam-based EvidenceHunt — argues the story is as much about business models as regulation: ad-funded clinical search and selling clinician search behaviour to pharma don't transfer to Europe, where clinicians distrust anything that looks commercial. We also examine what AI evidence search is measurably doing inside hospitals: more uniform knowledge across teams, fewer junior-to-senior consultations, faster decisions — and the open question of whether that convergence improves care or narrows clinical thinking. Guest: Philippe Habets, MD PhD, CEO & co-founder, EvidenceHunt (Amsterdam) What the conversation covers: - Why OpenEvidence left Europe: EU AI Act vs the ad-based and data-selling business model - What hospitals did after OpenEvidence's exit — governance, procurement, shadow AI use - How AI literature search changes clinical decision making and medical hierarchies - Automation bias, tunnel vision and who is liable when AI is wrong - Guardrails in practice: PII stripping, refusing clinical advice, reformulating case questions into research questions - Why LLM answers differ between tools — and the omission problem in complex patients - Living guidelines: automating systematic literature reviews and guideline updates (some protocols are 17 years old) - Should patients have access to the same evidence tools as clinicians? - EvidenceHunt vs OpenEvidence: data sources, GDPR, medical device regulation - What won't change in healthcare AI in the next three years Previous episode with Philippe Habets (2023): https://www.youtube.com/watch?v=F8tC0B4NvpM CHAPTERS 00:00 Introduction 03:11 OpenEvidence leaves Europe: what it meant for a European competitor 04:31 No user spike — but hospitals started asking questions 06:54 What EvidenceHunt is: from PubMed frustration to systematic reviews 11:35 How clinicians actually adopt AI evidence tools 13:46 Uniform knowledge, fewer senior consultations: measured effects on clinical thinking 16:24 Tunnel vision, automation bias and the liability question 18:04 Guardrails in practice: PII stripping and refusing clinical advice 20:31 The omission problem: evidence is group statistics, patients are N of 1 23:26 The real reason OpenEvidence left: ads, data-selling and European distrust 29:03 Should patients have the same evidence tools as clinicians? 31:51 Why disclaimers aren't enough — safeguards must be enforced in the product 33:43 Living guidelines: automating updates for protocols up to 17 years old 40:00 The biggest product challenge: too many features, one clean interface 41:40 What won't change in healthcare AI in the next three years FACES OF DIGITAL HEALTH Website: https://www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com LinkedIn: https://www.linkedin.com/company/faces-of-digital-health Spotify: https://open.spotify.com/show/4cElKJHrauyP6QJQaCkvdY Apple Podcasts: https://podcasts.apple.com/gb/podcast/faces-of-digital-health/id1194284040 #digitalhealth #healthcareAI #OpenEvidence #EUAIAct #clinicaldecisionsupport #evidencebasedmedicine #healthtech
Could you have PCOS and not know it? You sure can, says reproductive endocrinologist and menopause specialist Dr. Carla DiGirolamo, who is hopeful that the recent renaming of the condition from “polycystic ovary syndrome” (PCOS) to “polyendocrine metabolic ovarian syndrome” (PMOS) will help raise awareness—and improve care. This episode breaks down what PMOS actually is, why the new name matters, and how this androgen‑driven metabolic condition shows up across the lifespan, from irregular cycles and fertility struggles to increased cardiometabolic risk, especially once you hit the menopause transition. We also cover treatment options including metformin, inositol, and compelling new research on GLP‑1 receptor agonists, plus what all of this means for active midlife women when it comes to fueling, Reds/LEA risk, resistance training, and long‑term glucose control.Carla DiGirolamo, MD, PhD, is a Double Board Certified Reproductive Endocrinologist and Obstetrician/Gynecologist specializing in women's performance and menopausal medicine. She is also a Crossfit Level 1 trainer, Certified Nutrition Coach, and member of CrossFit Medical Society. She is a MedFit Care provider and provides weekly workouts and medical updates at her Substack Athletic Aging. She is an Endocrine Consultant for Wild Health and Women's Health Director at Eternal Health. Dr. DiGirolamo is now seeing patients for virtual consultations for menopausal care and performance optimization. Visit her website drcarlad.com to learn more about her services and schedule an appointment.Join us at Feisty Fest September 18-20, 2026: https://feisty.co/events/feisty-fest/Join the Feisty Strong STRONG Club: https://feisty.co/training/strong-club/ and use code: HITPLAY15 to save 15%Sign up for our FREE Feisty 40+ newsletter: https://feisty.co/feisty-40/Learn More about our 2026 Feisty Events, including Bike Camps and Cycling Trips: https://feisty.co/events/Follow Us on Instagram:Feisty Menopause: @feistymenopauseHit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Previnex: Get 20% off your order with code FEISTYBRAIN at https://www.previnex.com/ Wahoo: Use the code FEISTY2026 to get a free Headwind Smart Fan (value $300) with the purchase of a Wahoo KICKR RUN at https://shorturl.at/WVhdr
TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes
What's new in pancreas research? Tune in to Heard on the Street from ADA 2026 as Dr. Jordan Wright of Vanderbilt University highlights the latest discoveries from his lab and explores cutting edge advances shaping the future of diabetes research.
Neurological disease is one of the leading causes of morbidity and mortality around the world, yet many people in low and middle income countries have never had access to a neurologist. In this episode, Farrah Mateen, MD, PhD, the director of the new Center for Global Neurology at the Robert J. Havey, MD Institute for Global Health, talks about her career path to medicine and her passion for expanding access to neurological care worldwide.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Localized HR-Positive Breast Cancer | Faculty Presentation 1: Advances in the Use of Endocrine Therapy for Localized HR-Positive Breast Cancer — Harold J Burstein, MD, PhD CME information and select publications
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RNZ865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Moving Immunotherapy FORWARD in Melanoma: FOrum on Real-World Applications of Recent Data for Community Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KUG865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 16, 2027.Contemporary HIV Management: Therapeutic Advances and Real-World Approaches to Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KUG865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 16, 2027.Contemporary HIV Management: Therapeutic Advances and Real-World Approaches to Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RNZ865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Moving Immunotherapy FORWARD in Melanoma: FOrum on Real-World Applications of Recent Data for Community Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Bristol Myers Squibb and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
Dr. Dave Rabin, MD, PhD, a board-certified psychiatrist, neuroscientist, and author of A Simple Guide to Being Alive, joins Max to explain why modern life feels so overwhelming, how anxiety can be understood as a signal from the body, and what simple tools can help restore a sense of safety, calm, and connection.This episode is proudly sponsored by:AG1 is my favorite multivitamin now in delicious new flavors! Enjoy a free 1 year supply of vitamin D and 5 free AG1 travel packs with your first purchase. All you have to do is visit drinkag1.com/GENIUS.Timeline Nutrition makes MitoPure—a purified form of urolithin A, which studies suggest may provide powerful mitochondrial support for energy and longevity. Go to http://timelinenutrition.com/max for up to 39% off of mitopure gummies
How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Funda Meric-Bernstam, MD, the department chair and Endowed Nellie B. Connally Chair in Breast Cancer, in the Department of Investigational Cancer Therapeutics, medical director of the Khalifa Institute for Personalized Cancer Therapy, and a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston; as well as a regular member of Cancer Biology at the University of Texas Houston Graduate School of Biomedical Sciences.Drs Camidge and Meric-Bernstam discussed Dr Meric-Bernstam's evolution from a science-focused student into a leader in precision oncology and early-phase drug development. Dr Meric-Bernstam was raised in a hybrid fashion between the US and Turkey, attending a science-focused boarding school before beginning medical school in Turkey and ultimately restarting her medical education at the Yale School of Medicine in New Haven, Connecticut. Drawn to both the immediacy of surgery and the questions of basic science, she pursued a surgical residency with built-in research time, spending 2 years at the National Institute of Health studying translational regulation, an experience she credited with making her fearless in tackling the unfamiliar.In this discussion, Dr Meric-Bernstam offered a candid look at building a career without a clear roadmap. She emphasized that clinician-investigators must work hard, arguing that a meaningful clinical presence sharpens translational research by revealing patients' true unmet needs. Her work spanning cell signaling, mTOR biology, window-of-opportunity trials, and genomic testing led her to direct MD Anderson's personalized cancer therapy efforts and grow its phase 1 program.Beyond administration, Meric-Bernstam reflected on lessons from the lab, including a year of lost data that taught her to scrutinize primary results at every step, and her conviction in patient-derived models and co-clinical trials. Ultimately, Dr Meric-Bernstam described a transformational moment in oncology, where AI, comprehensive profiling, and newly druggable targets will reshape combination therapy. She concluded by reaffirming her mission to improve cancer outcomes, calling it the best job in the world.
Dr. Majid Fotuhi earned his PhD in neuroscience from Johns Hopkins University in 1992 and his medical degree from Harvard Medical School in 1997. Currently, he's an adjunct professor at the Mind Body Institute at Johns Hopkins University and teaches at George Washington University and Harvard Medical School. With 37 years of experience in teaching, clinical practice, and neuroscience research, Dr. Fotuhi has pioneered a multidisciplinary approach to enhancing brain vitality and cognitive performance at any age. His groundbreaking brain fitness program combines a comprehensive baseline brain portfolio assessment with 12 biweekly brain training sessions. This program targets lifestyle optimization and cognitive stimulation to improve memory, focus, and overall brain health. His program has delivered measurable success for patients dealing with memory loss due to aging, concussions, and ADHD, and he's been published in numerous peer-reviewed journals. He's also the author of three books, including his most recent titled The Invincible Brain. Links: drfotuhi, Instagram, and LinkedIn
© 2020-2026 Ivy Podcast Discovery LLC
